Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells
Open Access
- 30 May 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 26 (12), 2538-2545
- https://doi.org/10.1038/leu.2012.141
Abstract
Multiple myeloma is a plasma cell neoplasm residing in bone marrow. Despite advances in myeloma therapies, novel therapies are required to improve patient outcomes. CD47 is highly expressed on myeloma cells and a potential therapeutic candidate for myeloma therapies. Flow cytometric analysis of patient bone marrow cells revealed that myeloma cells overexpress CD47 when compared with non-myeloma cells in 73% of patients (27/37). CD47 expression protects cells from phagocytosis by transmitting an inhibitory signal to macrophages. Here we show that blocking CD47 with an anti-CD47 monoclonal antibody increased phagocytosis of myeloma cells in vitro. In xenotransplantation models, anti-CD47 antibodies inhibited the growth of RPMI 8226 myeloma cells and led to tumor regression (42/57 mice), implicating the eradication of myeloma-initiating cells. Moreover, anti-CD47 antibodies retarded the growth of patient myeloma cells and alleviated bone resorption in human bone-bearing mice. Irradiation of mice before myeloma cell xenotransplantation abolished the therapeutic efficacy of anti-CD47 antibodies delivered 2 weeks after radiation, and coincided with a reduction of myelomonocytic cells in spleen, bone marrow and liver. These results are consistent with the hypothesis that anti-CD47 blocking antibodies inhibit myeloma growth, in part, by increasing phagocytosis of myeloma cells.Keywords
This publication has 36 references indexed in Scilit:
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumorsProceedings of the National Academy of Sciences of the United States of America, 2012
- Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapyBlood, 2011
- Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic LeukemiaCancer Research, 2011
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin LymphomaCell, 2010
- Dominant role of CD47–thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone diseaseBlood, 2009
- Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cellsProceedings of the National Academy of Sciences of the United States of America, 2009
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid PhagocytosisCell, 2009
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem CellsCell, 2009
- Role for CD47-SIRPα signaling in xenograft rejection by macrophagesProceedings of the National Academy of Sciences of the United States of America, 2007
- A bivalent single-chain Fv fragment against CD47 induces apoptosis for leukemic cellsBiochemical and Biophysical Research Communications, 2004